Abstract c-MYC (MYC) is a major driver of prostate cancer tumorigenesis and progression.
Although MYC is overexpressed in both early and metastatic disease and associated with …

Prostate cancer (PCa) is the most common non-cutaneous cancer in men. The androgen
receptor (AR), a ligand-activated transcription factor, constitutes the main drug target for …

The androgen receptor (AR) is the principal therapeutic target in prostate cancer. For the
past 70 years, androgen deprivation therapy (ADT) has been the major therapeutic focus …

Prostate cancer, the majority of which is adenocarcinoma, is the most common epithelial
cancer affecting a majority of elderly men in Western nations. Its manifestation, however …

Androgen receptor (AR) in prostate cancer (PCa) can drive transcriptional repression of
multiple genes including MYC, and supraphysiological androgen is effective in some …

The transcript encoding the proto-oncogene MYC is commonly overexpressed in prostate
cancer (PC). MYC protein abundance is also increased in the majority of cases of advanced …

Despite recent therapeutic advances, prostate cancer remains a leading cause of cancer-
related death. A subset of castration-resistant prostate cancers become androgen receptor …

Understanding the intricacies of lethal prostate cancer poses specific challenges due to
difficulties in accurate modeling of metastasis in vivo. Here we show that NPK EYFP mice …

Increased expression of the full-length androgen receptor (AR-FL) and AR splice variants
(AR-Vs) drives the progression of castration-resistant prostate cancer (CRPC). The levels of …

Comprehensive genomic studies have delineated key driver mutations linked to disease
progression for most cancers. However, corresponding transcriptional changes remain …